Sunday, May 31, 2020

WuXi AppTec China Sites Resume Operations after Extended Lunar New Year Holiday

WuXi AppTec China Sites Resume Operations after Extended Lunar New Year Holiday SHANGHAI, February 12, 2020 - With the end of the extended Lunar New Year holiday, WuXi AppTec sites in China have resumed operations today, with the exception of our site...

WuXi Healthcare Forum 2020 – Solving Tomorrow’s Health Challenges

WuXi Healthcare Forum 2020 – Solving Tomorrow’s Health Challenges To Be Determined|The St. Regis Shanghai Jingan, Shanghai, China Dear Colleagues and Friends, Given current efforts to address the coronavirus outbreak, the organizing committee of the WuXi Healthcare Forum has decided to postpone this event, originally scheduled for...

WuXi Advanced Therapies Launches New World-Class AAV Vector Suspension Platform

New AAV Vector Suspension platform complements integrated capabilities – enabling cell and gene therapies to be developed, manufactured, and released faster and with greater predictability globally. January 13, 2020 – Philadelphia, PA - WuXi Advanced Therapies, a leading global Contract Development...

WuXi STA Opens Oligonucleotide Large-Scale Manufacturing Facility

State-of-the-art facility expands WuXi STA's capacity and capability for this novel modality, providing a one-stop shop from preclinical to commercial Shanghai, January 3, 2020: STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – today announced the...

TDI Serves as a Bridge Between Academia and Industry, Leveraging All It Needs for Innovation

By Rich Soll, Senior Advisor, Strategic Initiatives, WuXi AppTec (@richsollwx) and WuXi AppTec Content Team The translation of academic discoveries into therapeutic products remains an issue despite passage of the Bayh-Dole Act (or Patent and Trademark Law Amendments...

Subscribe to our Newsletter

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

INNOVATION THAT MATTERS